– High throughput system provides STAT results in about 80 minutes – March 31, 2020 (Ann Arbor, Michigan) NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to hospital and commercial reference laboratories, announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for...

March 12, 2020 (Ann Arbor, Michigan)  NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, announced today its plans for a SARS-CoV-2 Assay for use on its high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems.  SARS-CoV-2 is the Coronavirus that has been determined to...

Ann Arbor, MI (July 23, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the launch of CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) are herpes viruses found in up to 90% of the adult population.  Usually latent, the presence...

Ann Arbor, MI (June 21, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the launch of CE-IVD assays for Hepatitis B virus (HBV) and Hepatitis C virus (HCV). Hepatitis infections are more frequent in immunocompromised populations than in the general population with lower rates of spontaneous recovery...